EGFR and adenocarcinoma: Lineage transition from adenocarcinoma (AD) to aggressive neuroendocrine (NE) derivatives is a common type of cancer cell plasticity in androgen deprivation therapy–treated (ADT-treated) prostate AD (ADPC) and epidermal growth factor receptor (EGFR) inhibitor–treated lung AD (LUAD) (2).